FREE ELECTRONIC LIBRARY - Dissertations, online materials

«PFB PIL PACKAGE LEAFLET: INFORMATION FOR THE USER Latanoprost Pfizer 50 Micrograms/ml Eye Drops, Solution Latanoprost Read all of this leaflet ...»



Latanoprost Pfizer 50 Micrograms/ml Eye Drops, Solution


Read all of this leaflet carefully before you start using this medicine. Even if you have

already used Latanoprost Pfizer or a similar medicine before, we advise you to read

this text carefully. The information may have been changed.

• Keep this leaflet. You may need to read it again.

• If you have any further questions, ask your doctor or the doctor treating your child or your pharmacist.

• This medicine has been prescribed for you or for your child. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.

• If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or the doctor treating your child or your pharmacist. See section 4.

In this leaflet:

1. What Latanoprost Pfizer is and what it is used for

2. Before you use Latanoprost Pfizer

3. How to use Latanoprost Pfizer

4. Possible side effects

5. How to store Latanoprost Pfizer

6. Further information

1. What Latanoprost Pfizer is and what it is used for Latanoprost Pfizer belongs to a group of medicines known as prostaglandin analogues. It works by increasing the natural outflow of fluid from inside the eye into the bloodstream.

Latanoprost Pfizer is used to treat conditions known as open angle glaucoma and ocular hypertension in adults. Both of these conditions are linked with an increase in the pressure within your eye, eventually affecting your eye sight.

IE d LP 009 Page 1 2013-0003455 PFB PIL Latanoprost Pfizer is also used to treat increased eye pressure and glaucoma in all ages of children and babies.

2. Before you use Latanoprost Pfizer Latanoprost Pfizer can be used in adult men and women (including the elderly) and in children from birth to 18 years of age. Latanoprost Pfizer has not been investigated in prematurely born infants (less than 36 weeks gestation).

Do not use Latanoprost Pfizer if you are

• Allergic (hypersensitive) to latanoprost or any of the other ingredients of Latanoprost Pfizer (see section 6 for the list of ingredients in your medicine)

• Pregnant or trying to become pregnant

• Breast-feeding Take special care with Latanoprost Pfizer Talk to your doctor or the doctor treating your child or your pharmacist before you take Latanoprost Pfizer or before you give this to your child if you think any of the following apply

to you or your child:

• If you or your child are about to have or have had eye surgery (including cataract surgery)

• If you or your child suffer from eye problems (such as eye pain, irritation or inflammation, blurred vision)

• If you or your child know that you suffer from dry eyes

• If you or your child have severe asthma or your asthma is not well controlled

• If you or your child wear contact lenses. You can still use Latanoprost Pfizer, but follow the instruction for contact lens wearers in Section 3

• If you have suffered or are currently suffering from a viral infection of the eye caused by the herpes simplex virus (HSV) Taking other medicines Latanoprost Pfizer may interact with other medicines. Please tell your doctor, the doctor treating your child or pharmacist if you or your child are taking or have taken any other medicines including those medicines (or eye drops) obtained without a prescription.

–  –  –

Pregnancy Do not use Latanoprost Pfizer when you are pregnant. Tell your doctor immediately if you are pregnant, think you are pregnant, or are planning to become pregnant.

Breast-feeding Do not use Latanoprost Pfizer when you are breast-feeding.

Driving and using machines Latanoprost Pfizer has minor or moderate influence on the ability to drive and use machines.

When you use Latanoprost Pfizer you might have blurred vision, for a short time. If this happens to you, do not drive or use any tools or machines until your vision becomes clear again Important information about some of the ingredients of Latanoprost Pfizer Latanoprost Pfizer contains a preservative called benzalkonium chloride.

• Benzalkonium chloride may cause eye irritation.

• Avoid contact with soft contact lenses.

• If you or your child wears contact lenses, remove contact lenses prior to application and wait at least 15 minutes before reinsertion.

• Benzalkonium chloride is known to discolour soft contact lenses.

See the instructions for contact lens wearers in Section 3.

3. How to use Latanoprost Pfizer Always use Latanoprost Pfizer exactly as your doctor or the doctor treating your child has told you. You should check with your doctor or the doctor treating your child or pharmacist if you are not sure.

The usual dosage for adults (including the elderly) and children is one drop once a day in the affected eye(s). The best time to do this is in the evening.

Do not use Latanoprost Pfizer more than once a day, because the effectiveness of the treatment can be reduced if you administer it more often.

Use Latanoprost Pfizer as instructed by your doctor or by the doctor treating your child until your doctor tells you to stop.

Contact lens wearers

–  –  –

If you or your child wear contact lenses, you should remove them before using Latanoprost Pfizer. After using Latanoprost Pfizer you should wait 15 minutes before putting your contact lenses back in.

Instructions for use

1. Wash your hands and sit or stand comfortably.

2. Unscrew the protective cap. The protective cap should be retained.

3. Use your finger to gently pull down the lower eyelid of your affected eye.

4. Place the tip of the dropper container close to, but not touching your eye.

5. Squeeze the dropper container gently so that only one drop goes into your eye, then release the lower eyelid.

6. Press a finger against the corner of the affected eye by the nose. Hold for 1 minute whilst keeping the eye closed.

7. Repeat in your other eye if your doctor has told you to do this.

8. Put the protective cap back on the dropper container.

If you use Latanoprost Pfizer with other eye drops Wait at least 5 minutes between using Latanoprost Pfizer and taking other eye drops.

–  –  –

If you use more Latanoprost Pfizer than you should If you put too many drops into your eye, you may experience some minor irritation in your eye and your eyes may water and turn red, this should pass, but if you are worried contact your doctor or the doctor treating your child for advice.

Contact your doctor as soon as possible if you or your child swallows Latanoprost Pfizer accidentally.

If you forget to use Latanoprost Pfizer Carry on with the usual dosage at the usual time. Do not take a double dose to make up for the dose you have forgotten. If you are unsure about anything talk to your doctor or pharmacist.

If you stop using Latanoprost Pfizer You should speak to your doctor or the doctor treating your child if you want to stop taking Latanoprost Pfizer.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. Possible side effects Like all medicines, Latanoprost Pfizer can cause side effects, although not everybody gets them.

The following are known side effects of using Latanoprost Pfizer:

Very common (likely to affect more than 1 in 10 people):

• A gradual change in your eye colour by increasing the amount of brown pigment in the coloured part of the eye known as the iris. If you have mixed-colour eyes (blue-brown, grey-brown, yellow-brown or green-brown) you are more likely to see this change than if you have eyes of one colour (blue, grey, green or brown eyes). Any changes in your eye colour may take years to develop although it is normally seen within 8 months of treatment. The colour change may be permanent and may be more noticeable if you use Latanoprost Pfizer in only one eye. There appears to be no problems associated with the change in eye colour. The eye colour change does not continue after Latanoprost Pfizer treatment is stopped.

• Redness of the eye.

• Eye irritation (a feeling of burning, grittiness, itching, stinging or the sensation of a foreign body in the eye).

–  –  –

• A gradual change to eyelashes of the treated eye and the fine hairs around the treated eye, seen mostly in people of Japanese origin. These changes involve an increase of the colour (darkening), length, thickness and number of your eye lashes.

Common (likely to affect less than 1 in 10 people):

• Irritation or disruption to the surface of the eye, eyelid inflammation (blepharitis), eye pain and light sensitivity (photophobia).

Uncommon (likely to affect less than 1 in every 100 people):

• Eyelid swelling, dryness of the eye, inflammation or irritation of the surface of the eye (keratitis), blurred vision and conjunctivitis.

• Skin rash.

Rare (likely to affect less than 1 in every 1000 people):

• Inflammation of the iris, the coloured part of the eye (iritis/uveitis); swelling of the retina (macular oedema), symptoms of swelling or scratching/damage to the surface of the eye, swelling around the eye (periorbital oedema) misdirected eyelashes or an extra row of eyelashes.

• Skin reactions on the eyelids, darkening of the skin of the eyelids.

• Asthma, worsening of asthma and shortness of breath (dyspnoea).

Very rare (likely to affect less than 1 in 10,000 people):

• Worsening of angina in patients who also have heart disease, chest pain, sunken eye appearance (eye sulcus deepening).

Patients have also reported the following side-effects: fluid filled area within the coloured part of the eye (iris cyst), headache, dizziness, awareness of heart rhythm (palpitations), muscle pain and joint pain and developing a viral infection of the eye caused by the herpes simplex virus (HSV).

Side effects seen more often in children compared to adults are: runny itchy nose and fever.

In very rare cases, some patients with severe damage to the clear layer at the front of the eye (the cornea) have developed cloudy patches on the cornea due to calcium build-up during treatment.

Reporting of side effects If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effect not listed in this leaflet. You can also report side effects directly via IMB

–  –  –

Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1

6762517. Website: www.imb.ie; e-mail: imbpharmacovigilance@imb.ie By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Latanoprost Pfizer Keep out of the reach and sight of children.

Do not use Latanoprost Pfizer after the expiry date which is stated on the carton and dropper container. The expiry date refers to the last day of that month.

Store the unopened dropper container in a refrigerator (between 2°C and 8°C), protected from light.

After opening the dropper container it is not necessary to store the dropper container in a refrigerator but do not store it above 25°C. Use within 4 weeks of opening. When you are not using Latanoprost Pfizer, keep the dropper container in the outer carton, in order to protect from light.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

6. Further information What Latanoprost Pfizer contains The active substance is latanoprost.

1 ml of eye drops contains 50 micrograms of latanoprost.

2.5 ml of eye drops, solution (content of a dropper container) contains 125 micrograms of latanoprost.

One drop contains approximately 1.5 micrograms latanoprost.

The other ingredients are: benzalkonium chloride, sodium chloride, sodium dihydrogen phosphate monohydrate (E339a) and anhydrous disodium phosphate (E339b) dissolved in water for injections.

What Latanoprost Pfizer looks like and contents of the pack Latanoprost Pfizer Eye Drops, Solution is a clear, colourless liquid.

Latanoprost Pfizer is available in pack sizes of 1, 3 and 6 cartons. Not all pack sizes may be marketed.

–  –  –

Each carton contains one dropper container of Latanoprost Pfizer. Each dropper container contains 2.5 ml of Latanoprost Pfizer Eye Drops, Solution.

Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland Manufacturer: Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs, Belgium.

This medicinal product is authorised in the Member States of the EEA under the following


Austria, Belgium, Denmark, Finland, France, Greece, Hungary, Ireland, Italy, Luxembourg, Netherlands, Portugal, United Kingdom: Latanoprost Pfizer Spain: Latanoprost Pharmacia Germany: Latanoprost Pfizer 50 Mikrogramm/ml Augentropfen This leaflet was last revised in: 04/2014 Ref: dLP 5_0 IE

Similar works:

«Working Paper 60 OHS Inspectors and Psychosocial Risk Factors: Evidence from Australia Professor Richard Johnstone, Socio-Legal Research Centre, Griffith Law School, Griffith University, Queensland (also Co-Director of the National Research Centre for OHS Regulation) Professor Michael Quinlan and Ms Maria McNamara, School of Organisation and Management, The University of New South Wales, and Work and Health Research Team, University of Sydney October 2008 About the Centre The National Research...»

«ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Zometa 4 mg powder and solvent for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 4 mg zoledronic acid, corresponding to 4.264 mg zoledronic acid monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and solvent for solution for infusion White to off-white powder and clear, colourless solvent. 4. CLINICAL PARTICULARS 4.1 Therapeutic...»

«UP MS General Medicine major – subjects of the Pre-clinical module Course descriptions – academic year of 2014/2015 University of Pécs Medical School GENERAL MEDICINE Major STUDY PROGRAM 2014/2015 Subjects of the Pre-clinical module (obligatory subjects and criterion requirements) 1 UP MS General Medicine major – subjects of the Pre-clinical module Course descriptions – academic year of 2014/2015 5th semester OAP-BPR Internal Medicine: Propaedeutics _ 3 OAP-GT1 _ Pharmacology 1 5...»

«Ethical Human Psychology and Psychiatry, Volume 6, Number 1, Spring 2004 The Ethics and Science of Medicating Children Jacqueline A. Sparks The University of Rhode Island Kingston, RI Barry L. Duncan Institute for the Study of Therapeutic Change Ft. Lauderdale, FL Prescriptions for psychiatric drugs to children and adolescents have skyrocketed in the past 10 years. This article presents evidence that the superior effectiveness of stimulants and antidepressants is largely a presumption based on...»

«Medicines Formulary Ear, nose and throat Contents: 1. Otitis externa and otitis media 1 2. Ear wax — removal 3 3. Rhinitis 3 4. Nasal polyps and post nasal surgery 4 5. Nasal congestion 4 6. Facial surgery — post surgical prophylaxis of infection 4 7. Oral hygiene and prevention of oral infection 5 8. Dry mouth 5 9. Treatment of sore mouth and oral ulceration 5 10. Fungal infections of the mouth and throat 7 11. Epistaxis 7 12. Oral bleeding 7 13. Local anaesthesia prior to dental...»

«UT O RD O W HE T NG TI T GE EFFECTIVE HEALTH OUTREACH TO CULTURAL COMMUNITIES Produced by Patricia Ohmans Health Advocates Saint Paul, MN Marty Cushing Coordinator, Patient Link The Medtronic Foundation Reviewed by Jane Delgado, Ph.D., President Concha Orozco, Director, Institutional Development The National Alliance for Hispanic Health Washington, DC Sherry Deane Vice President National Black Women's Health Project Washington, DC Bob Mizerak National Director, Seniors in Community Service...»

«ENDING THE TOBACCO EPIDEMIC Progress Toward A Healthier Nation ENDING THE TOBACCO EPIDEMIC Progress Towards A Healthier Nation August 2012 Suggested Citation: U.S. Department of Health and Human Services. Ending the Tobacco Epidemic: Progress Toward a Healthier Nation. Washington: U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health, August 2012. To access this publication online, please go to http://www.hhs.gov/ash/initiatives/tobacco/. Table of Contents...»

«Recommendation from the Scientific Committee on Occupational Exposure Limits for carbon tetrachloride SCOEL/SUM/31 June 2009 European Commission Employment, Social Affairs and Inclusion Recommendation from the Scientific Committee on Occupational Exposure Limits for carbon tetrachloride Table of Contents 1. Occurrence/use 2. Health Significance 2.1 Toxicokinetics Biological monitoring 2.2 Acute toxicity 2.2.1 Human data 2.2.2 Animal data 2.3 Irritation and corrosivity 2.3.1 Human data 2.3.2...»

«Food labels Why do we have food labels? Food labels provide information to help us make healthier and safer food choices. They do the following: • Tell us which nutrients, in what amounts, are in a product • Warn us if a food contains food allergens • Inform us if the food is fresh or out of date • When necessary, explain how to store, prepare or cook the food we buy • List product ingredients • Give us information on where the food was produced and which company has marketed...»

«GENETIC VARIATIONS ASSOCIATED WITH RESISTANCE TO DOXORUBICIN AND PACLITAXEL IN BREAST CANCER by Irada Ibrahim-zada A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Laboratory Medicine and Pathobiology University of Toronto © Copyright by Irada Ibrahim-zada 2010 ii Genetic variations associated with resistance to doxorubicin and paclitaxel in breast cancer Irada Ibrahim-zada Doctor of Philosophy Department of Laboratory Medicine and...»

«CORTICOSTRIATAL REGULATION OF MEDIUM SPINY NEURON DENDRITIC REMODELING IN MODELS OF PARKINSONISM By Bonnie Gale Garcia Dissertation Submitted to the faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in Pharmacology May, 2010 Nashville, Tennessee Approved: Professor Ariel Y. Deutch Professor Randy D. Blakely Professor Danny G. Winder Professor Eugenia V. Gurevich Professor P. Jeffrey Conn Copyright © 2010 by...»

«Measurement-Based Deep Venous Thrombosis Screening System Julian Guerrero1, S.E. Salcudean1, James A. McEwen1,2, Bassam A. Masri2, and Savvas Nicolaou3 1 Department of Electrical & Computer Engineering, University of British Columbia, 2356 Main Mall, Vancouver BC V6T 1Z4, Canada 2 Department of Orthopaedics, University of British Columbia, 3114 910 W 10th Ave, Vancouver BC V5Z 4E3, Canada 3 Department of Radiology, Vancouver Hospital & Health Sciences Centre, 855 West 12th Ave, Vancouver BC...»

<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.